Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

TCR2 Therapeutics Inc. (TCRR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.8600-0.1000 (-5.10%)
At close: 04:00PM EDT
1.9500 +0.09 (+4.84%)
After hours: 04:19PM EDT
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    TCR2 Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 7,600 shares of TCR2’s common stock to 2 new non-executive employees. The stock options were granted as an inducement material to the employee

  • Simply Wall St.

    What Kind Of Shareholders Hold The Majority In TCR2 Therapeutics Inc.'s (NASDAQ:TCRR) Shares?

    The big shareholder groups in TCR2 Therapeutics Inc. ( NASDAQ:TCRR ) have power over the company. Institutions often...

  • GlobeNewswire

    TCR² Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

    - gavo-cel Phase 1 trial dataset anticipated in September 2022- Initial TC-510 Phase 1 data anticipated in 2H 2022 - Expansion of manufacturing capacity and commencement of gavo-cel clinical trial material production at ElevateBio BaseCamp CAMBRIDGE, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, today announced financial results for th

Advertisement
Advertisement